Recommended Dose for Farxiga in CKD Stage 3
The recommended dose of dapagliflozin (Farxiga) for an adult with CKD stage 3 is 10 mg orally once daily for kidney and cardiovascular protection. 1
Dosing Algorithm by CKD Stage 3 Substage
CKD 3a (eGFR 45-59 mL/min/1.73 m²)
- Dose: 10 mg once daily 1
- No dose adjustment needed regardless of indication
- Full kidney and cardiovascular benefits maintained
CKD 3b (eGFR 30-44 mL/min/1.73 m²)
- Dose: 10 mg once daily 2, 1
- Same dose as CKD 3a
- Initiation is safe and effective down to eGFR ≥25 mL/min/1.73 m² 1
Critical Context: Indication Matters
For kidney/cardiovascular protection (CKD, heart failure, CV risk reduction):
- Use 10 mg once daily across all of CKD stage 3 1
- This is the evidence-based dose from DAPA-CKD trial 3
For glycemic control only (if that's the sole goal):
- CKD 3a: Can use 5-10 mg daily 1
- CKD 3b: Farxiga is NOT recommended for glycemic control with eGFR <45 mL/min/1.73 m² as it becomes ineffective for glucose lowering 1
- However, you should still prescribe it at 10 mg for kidney/CV protection even if glucose lowering is minimal
Evidence Strength
The 2024 BMJ guideline provides a strong recommendation for SGLT2 inhibitors in patients at very high risk of CKD progression, with high certainty evidence for reducing all-cause mortality and kidney failure 4. The 2022 ADA/KDIGO consensus specifically recommends SGLT2 inhibitors with proven kidney or cardiovascular benefit for patients with eGFR ≥20 mL/min/1.73 m² 2.
The DAPA-CKD trial (the pivotal study for Farxiga in CKD) used 10 mg once daily and demonstrated a 39% relative risk reduction in the primary composite outcome of sustained eGFR decline ≥50%, ESKD, or renal/cardiovascular death 3. This benefit was consistent across all CKD stages studied, including stage 4 CKD 5.
Key Clinical Pearls
Do NOT reduce the dose in CKD stage 3. The FDA label and guidelines are clear that 10 mg is the appropriate dose for kidney protection across the entire CKD 3 range 2, 1. The common misconception is that lower eGFR requires dose reduction—this is incorrect for dapagliflozin when used for kidney/CV indications.
Glucose-lowering efficacy diminishes as eGFR falls, but kidney and cardiovascular benefits are preserved 2. This is why the dose remains 10 mg even when glycemic effects wane.
Pre-initiation assessment: Check volume status and correct any volume depletion before starting 1. Consider proactive diuretic dose reduction in patients at high risk for hypovolemia 2.
Continue therapy if eGFR declines: If eGFR falls below 25 mL/min/1.73 m² while on treatment, continue Farxiga 10 mg daily—do not stop 1. The DAPA-CKD trial protocol specifically allowed continuation below initiation thresholds 2.
Safety Monitoring
Monitor for genital mycotic infections (6% incidence), volume depletion, and euglycemic ketoacidosis (rare but serious) 2. Adjust background insulin or sulfonylureas if present to mitigate hypoglycemia risk, though absolute risks are low at lower eGFR 2.
Withhold Farxiga for at least 3 days before major surgery or prolonged fasting to reduce ketoacidosis risk 1.